
author: Gerd Graßhoff title: Philosophy of Remdesivir date: "July 2020" lang: de
output: pdf_document: toc: true highlight: pygments fontsize: 10pt geometry: margin=1in
bibliography:

- CoronaVirus.bib

csl: chicago-note-bibliography-with-ibid.csl
style: numeric
titlepage: true link-citations: true book: false tables: true logo: assets/Hu-Logo.jpg number-sections:
true classoption: onside titlepage-text-color: "FFFFFF" titlepage-rule-color: "FFFFFF"
...

Contents

Background	2
Press Conference on Remdesivir at 29th April 2020	2
Research objects	3
References	5

Background

This research question refers to ongoing publications on corona research and might change in due course. In the public debate about early therapies concerning COVID-19 all sorts of drugs beside vaccines played a prominent role. It is scientifically established that it is not directly affecting the virus. This study aims to analyse the methodological issues of the dynamics of scientific understanding of the causal effects that the drug creates according to the global set of scientific publications on remdesivir

Press Conference on Remdesivir at 29th April 2020

CNN White House Press conference



Gilead-Logo

Das Mittel macht Anlegern Hoffnung.
(Foto: AFP)

Frankfurt. Das Medikament hilft, ist aber kein Wundermittel. Diese Bewertung zeichnet sich für den bislang wichtigsten Hoffnungsträger im Kampf gegen Covid-19, den vom US-Biotechkonzern Gilead entwickelten Wirkstoff Remdesivir ab.

Das amerikanische Nationale Institut für Allergien und Infektionskrankheiten (NIAID) hat am Mittwochabend erste vorläufige Daten aus einer großen, placebo-kontrollierten klinischen Studie mit fast 1100 Patienten publiziert.

Covid-19-Patienten, die stationär behandelt wurden, haben sich danach unter Remdesivir im Schnitt schneller erholt als Patienten, die nur ein Scheinmedikament (Placebo) erhielten. Sie konnten die Klinik im Durchschnitt nach elf Tagen verlassen, während das den Patienten der Vergleichsgruppe erst nach 15 Tagen möglich war.



Research objects

research objects = All abstracts of scientific publications since January 2020 about the possible treatment for coronavirus with remdesivir

empirical sources = Data Dimension

2020

Publication Year

Remdesivir AND COVID-19

Free text in full data

Save / Export

Workflow

Support

Gerd Gra...

FILTERS

FAVORITES

GROUPS

PUBLICATION YEAR

2020 1,818

RESEARCHER

FUNDER

COUNTRY OF FUNDER

RESEARCH ORGANIZATION

LOCATION - RESEARCH ORG...

RESEARCH CATEGORIES

PUBLICATION TYPE

SOURCE TITLE

PUBLISHER

JOURNAL LIST

OPEN ACCESS

PUBLICATIONS

1,818

DATASETS

3

GRANTS

0

PATENTS

0

CLINICAL TRIALS

61

POLICY DOCUMENTS

11

Show abstract

Sort by: Relevance

Title, Author(s), Bibliographic reference - About the metrics

Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease.

Valeria Avataneo, Amedeo de Nicolò, Jessica Cusato, Miriam Antonucci, Alessandra Manca, Alice Pa...

2020, Journal of Antimicrobial Chemotherapy - Article

BACKGROUND: Remdesivir has received significant attention for its potential application in the treatment of COVID-19, caused by SARS-CoV-2. Remdesivir has already been tested for Ebola virus disease t...

Altmetric 15

View PDF

Add to Library

Rapid review for the anti-coronavirus effect of remdesivir

Ziyi Li, Xiaojie Wang, Donglin Cao, Ruilin Sun, Cheng Li, Guowei Li

2020, Drug Discoveries & Therapeutics - Article

The outbreak of SARS-CoV-2 rapidly spread across China and worldwide. Remdesivir had been proposed as a promising option for treating coronavirus disease 2019 (COVID-19). We provided a rapid review to...

Altmetric 2

View PDF

Add to Library

Compassionate Use of Remdesivir in Covid-19.

Christian Hoffmann

2020, New England Journal of Medicine - Article

Altmetric 687

View PDF

Add to Library

Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies

Awadhesh Kumar Singh, Akriti Singh, Ritu Singh, Anoop Misra

2020, Diabetes & Metabolic Syndrome Clinical Research & Reviews - Article

BACKGROUND & AIMS: <AbstractText Label="BACKGROUND & AIMS">NlmCategory="OBJECTIVE">Remdesivir is a broad spectrum anti-viral drug that has shown to inhibit SARS-C...

Altmetric 6

View PDF

Add to Library

What do we know about remdesivir drug interactions?

Katherine Yang

2020, Clinical and Translational Science - Article

The global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted

ANALYTICAL VIEWS

RESEARCH CATEGORIES

11 Medical and Health Sciences	1,450
1103 Clinical Sciences	563
1117 Public Health and Health Services	355
1108 Medical Microbiology	327
06 Biological Sciences	171

OVERVIEW

Citations

13 K

Citations (Mean)

7.01


Publications (total)

OPEN ACCESS

All OA	1,605
Bronze	724
Green, Published	399
Pure Gold	276
Closed	213

RESEARCHERS

Geng-Fu Xiao	9
Wuhan Institute Of Virology, China	
Yao Zhao	8
ShanghaiTech University, China	
Leike Zhang	8
Wuhan Institute Of Virology, China	
Jean-Marc Rolain	8
Méditerranée Infection Foundation, France	
Xiuna Yang	8
ShanghaiTech University, China	



research question = Chronology of causal hypotheses on the effects of Remdesivir and the evolution of their empirical justification

References

- Covid-19 knowledge tree: <https://github.com/covid-19-net/covid-19-community/>